

**UCC Library and UCC researchers have made this item openly available.
Please [let us know](#) how this has helped you. Thanks!**

Title	Feeding melancholic microbes: MyNewGut recommendations on diet and mood
Author(s)	Dinan, Timothy G.; Stanton, Catherine; Long-Smith, Caitriona; Kennedy, Paul; Cryan, John F.; Cowan, Caitlin S. M.; Cenit, María Carmen; van der Kamp, Jan-Willem; Sanz, Yolanda
Publication date	2018-11-17
Original citation	Dinan, T. G., Stanton, C., Long-Smith, C., Kennedy, P., Cryan, J. F., Cowan, C. S. M., Cenit, M. C., van der Kamp, J.-W. and Sanz, Y. (2018) 'Feeding melancholic microbes: MyNewGut recommendations on diet and mood', Clinical Nutrition. doi:10.1016/j.clnu.2018.11.010
Type of publication	Article (peer-reviewed)
Link to publisher's version	http://dx.doi.org/10.1016/j.clnu.2018.11.010 Access to the full text of the published version may require a subscription.
Rights	© 2018, Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. https://creativecommons.org/licenses/by-nc-nd/4.0/
Embargo information	Access to this article is restricted until 12 months after publication by request of the publisher.
Embargo lift date	2019-11-17
Item downloaded from	http://hdl.handle.net/10468/7177

Downloaded on 2021-11-27T05:21:32Z

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

**Feeding melancholic microbes:
MyNewGut recommendations on diet and mood**

Timothy G. Dinan^{1,2}, Catherine Stanton^{1,3}, Caitriona Long-Smith¹, Paul Kennedy¹, John F. Cryan^{1,6}, Caitlin S.M. Cowan¹, Mamen Cenit Laguna⁴, Jan-Willem van der Kamp⁵, Yolanda Sanz⁴

1. APC Microbiome Ireland, University College Cork, Ireland
2. Department of Psychiatry and Neurobehavioural Science, University College Cork, Ireland
3. Teagasc, Moorepark, Ireland
4. Institute of Agrochemistry and Food Technology (IATA), National Council for Scientific Research (CSIC), Valencia, Spain
5. TNO Food and Nutrition, Zeist, Netherlands
6. Department of Anatomy and Neuroscience, University College Cork, Ireland

Corresponding author: Prof. Ted Dinan, APC Microbiome Ireland, University College Cork, Ireland t.dinan@ucc.ie

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Depression is a highly prevalent disorder which exerts a major economic impact in all European countries. The brain-gut-microbiota axis has been described as a new paradigm for advancing understanding and treatment of the disorder. There is now over-whelming evidence to support the fact that gut microbes have a major impact on central neurochemistry and behaviour, especially stress related disorders such as depression. Recent studies indicate that patients with depression have a gut dysbiosis. The reason for this dysbiosis is uncertain. Over recent decades, dietary patterns in Europe and elsewhere have undergone major compositional changes, with increased intakes of red meat, high fat foods, and refined sugars. Individuals who consume a Mediterranean diet have lower rates of depression and a recent study suggests that a Mediterranean diet may have antidepressant properties. Assuming this to be the case, which components of the Mediterranean diet mediate the effects? Highly levels of polyphenols or polyunsaturated fatty acids are obvious candidates. We in the MyNewGut consortium recommend that patients with depression or vulnerability to depression should be encouraged to enhance a plant-based diet with a high content of grains /fibres and fish.

Keywords: MyNewGut, depression, gut microbiota, diet, dysbiosis

61 **Background**

62 Depression is not only the common cold of psychiatric disorders but one of the most
63 prevalent medical conditions. In Europe the economic impact of depression
64 accounts for one third of the cost of all psychiatric and neurological disease (1).

65 While several subtypes of mood disorder have been described the most important in
66 terms of prevalence are major depression (unipolar) and bipolar affective disorder,
67 previously called manic depression. The point prevalence of major depression in
68 Europe is between 3% - 6% and it is clear that no society is immune to the disorder
69 (2). Despite major investment in studies exploring the biology of depression, it
70 remains a syndrome diagnosed by the presence of a cluster of symptoms (3) and not
71 by objective laboratory investigations. Most, though not all cases of depression arise
72 due to negative life events in a setting of psychosocial stress, with genetics and early
73 life adversity frequently yielding vulnerability to the disorder. The core features of
74 depression are low mood and/or anhedonia, the inability to feel enjoyment. Anxiety
75 is often an important feature of major depression, though it can be a distinct
76 disorder, often presenting as generalized anxiety disorder, panic disorder or
77 obsessive compulsive disorder.

78 Current pharmacotherapy in Europe and elsewhere for treating major depression
79 comprises the manipulation of monoaminergic systems (catecholaminergic and
80 serotonergic systems). (4). Clinical efficacy of these drugs is limited by a delayed
81 onset of action and a considerable proportion of patients (maybe as high as 40%)
82 who do not respond adequately to treatment (5). Psychological therapies, likewise
83 have limitations, and are used either on their own or in combination with
84 medication. Cognitive behaviour therapy (CBT) and mindfulness are the most

85 widely used and studied psychological therapies. For many patients a combination
86 of antidepressants and CBT/mindfulness is considered as the optimal therapy.

87 Over the past decade there has been a major focus on the role of inflammation in the
88 pathophysiology of depression and in determining vulnerability to the disorder. It is
89 established that major depression correlates with definite increases in pro-
90 inflammatory cytokines such as interleukin-1 (IL-1), IL-8 and TNF-alpha (6). These
91 cytokines potentially activate the hypothalamic-pituitary-adrenal axis (HPA) and may
92 play a major part in maintaining the HPA over-activation seen in depression(7).
93 Effective treatment of depression by whatever modality is accompanied by
94 suppression of pro-inflammatory cytokines and decreased activation of the HPA. It
95 is of interest from a nutritional perspective that a Mediterranean diet which is
96 viewed as having anti-inflammatory effects is associated with less depression than
97 standard northern European diets (8).

98 The FP7 EU project MyNewGut (www.mynewgut.eu) is a five-year initiative (2013-
99 2018) integrated by a highly multidisciplinary team that cooperates to disentangle
100 the role played by our gut microbiota, via interactions with lifestyle factors (e.g. diet,
101 eating habits, stress, etc.), in the regulation of pathways leading to the development
102 of obesity and behavioural disorders. In this review the views of the Consortium in
103 relation to diet and mood and how such effects are mediated by the microbiota are
104 laid out.

105 **New paradigm in mental health**

106 The brain-gut-microbiota axis is the focus of the latest paradigm not just in neuroscience, but
107 specifically in relation to mental health, and has been put forward as a potential watershed
108 development (9). There is now an ever accumulating volume of evidence to support the fact
109 that gut microbes have a major impact on central neurochemistry and behaviour, especially

110 stress related responses(10). In humans functional MRI (11) and electroencephalography(12)
111 have been used to support animal studies. Through what mechanism(s) do gut microbes exert
112 such significant central influence and how might targeting the brain-gut-microbiota axis
113 through dietary intervention yield effective therapies for patients with depression?
114 In reviewing the published literature on the brain-gut-microbiota axis and mental health the
115 main limitation at this point is the paucity of well designed, adequately powered clinical
116 studies. As has been pointed out elsewhere, a majority of papers so far published are from
117 the pre-clinical arena (9). Drawing major clinical conclusions from rodent studies is
118 problematic.

119 **Brain-gut microbe communication**

120 It is argued that gut microbe to brain communication is a black box of which we have limited
121 understanding (13). However, this may be considered as an overly pessimistic analysis of the
122 current state of knowledge. We know that the brain-gut-microbiota axis is a bidirectional
123 communication system which enables gut microbes to communicate with the brain, and the
124 brain in turn to communicate with the gut (14). While brain-gut communication has been the
125 subject of research for decades an exploration of gut microbes as an important vehicle within
126 this context has only recently been proposed. The mechanisms of signal transmission are
127 complex and involve neural, endocrine, immune, and metabolic pathways. Preclinical studies
128 have implicated the vagus nerve, that long meandering nerve, as a fundamental neural route
129 of communication between gut microbes in the periphery and centrally-mediated behavioural
130 effects, as demonstrated by the elimination of central *Lactobacillus rhamnosus* (JB1) effects
131 following a full truncal vagotomy (15). Epidemiological studies have demonstrated that
132 individuals who underwent a full truncal vagotomy for treatment of peptic ulcer disease have
133 a diminished risk of Parkinson's disease as they age (16). The gut microbiota also regulates

134 brain monoamines, such as serotonin, by altering levels of precursors; for example
135 *Bifidobacterium longum* 35624 has been shown to increase plasma tryptophan levels and thus
136 impact central 5-HT (17). Tryptophan is the amino acid precursor of serotonin and the
137 human brain has limited storage capacity, therefore requiring a continuous supply from the
138 periphery. This supply originates from both a dietary source and from intestinal
139 bifidobacteria who can synthesise the molecule.

140 Intriguingly, many gut bacteria can synthesise and release neurotransmitters. *Lactobacillus*
141 and *Bifidobacterium* species produce gamma-aminobutyric acid (GABA): *Escheridia*,
142 *Bacillus* and *Saccharomyces spp.* produce noradrenaline: *Candida*, *Streptococcus*,
143 *Escheridia* and *Enterococcus spp.* can produce 5-HT: *Bacillus* can produce dopamine: and
144 *Lactobacillus* can produce acetylcholine (18, 19). These gut-originated neurotransmitters can
145 cross the mucosal layer of the intestine, though it is highly unlikely they directly influence
146 brain chemistry. Even if they enter the blood stream, which has not been demonstrated, they
147 cannot cross the blood brain barrier (BBB). Their impact on brain function therefore is most
148 likely to occur by acting locally on the enteric nervous system. Short chain fatty acids
149 (SCFAs), which include butyrate, propionate and acetate are metabolic products of gut
150 microbial activity and are a rich energy source. They can exert central effects either through
151 conventional GPCRs (G-protein coupled receptors), though such receptors are sparsely
152 concentrated in the mammalian brain and the half-life of SCFAs is exceedingly short in the
153 plasma. Alternatively, they may behave as epigenetic modulators by inhibiting histone
154 deacetylases (HDACs)(20). The immune system provides another gut to brain
155 communication pathway, signalling by way of cytokine molecules (21). Such molecules
156 produced at the level of the gut can travel via the bloodstream to the brain. However, in
157 normal physiological circumstances they do not cross the BBB, but there is accumulating
158 evidence to support the view that they signal across the BBB and influence brain regions such

159 as the paraventricular nucleus of hypothalamus and circumventricular organs where the BBB
160 is deficient. If plasma levels of the cytokines IL-1 and IL-6 are elevated by infection or
161 otherwise they activate the core stress system, the HPA, bringing about the release of cortisol.
162 This is viewed as the most potent activating mechanism of the stress system and is of special
163 relevance in disorders such as the depression that emerges with interferon therapy for
164 hepatitis or melanoma (22).

165 **Psychopathology and gut dysbiosis**

166 There is increasing evidence that some psychiatric disorders such as depression may be
167 associated with a gut dysbiosis, a microbial imbalance. The extent to which such a dysbiosis
168 is central to the pathophysiology of depression has yet to be fully elucidated.

169 **Depression**

170 Lyte et al (23) found that oral gavage of the pathogen *Campylobacter jejuni*, in tiny
171 subclinical doses, which failed to exert an immune response, resulted in anxiety-type
172 behaviour in rodents. They also found that areas of brainstem, such as the nucleus tractus
173 solitarius and lateral parabrachial nucleus, are involved in the processing that results in the
174 autonomic, neuroendocrine and behavioural responses induced by the gavage.

175 A recently published epidemiological analysis supports the link between gut infection and
176 anxiety. Bruch analysed the Medical Expenditure Panel Survey (MEPS) to prospectively
177 determine a relationship between intestinal infection and future onset of an anxiety disorder
178 (24). The data for all respondents who were 18 years of age or older and who did not have an
179 anxiety disorder at baseline were included. Within the study population, there were 2577
180 subjects with an intestinal infection in Round 1 and 4239 with an anxiety disorder
181 commencing subsequently. In total an intestinal infection in Round 1 was associated with a

182 significantly increased odds ratio of a subsequent emergent anxiety disorder. This major
183 epidemiological study provides solid evidence for a link between intestinal infection and the
184 development of anxiety.

185 O'Mahony and colleagues studied the gut microbiota in a maternal separation model of
186 depression in rats (25). They reported an elevation in corticosterone in such animals,
187 together with an increase in pro-inflammatory cytokines and a decrease in the diversity of gut
188 microbes. In a recent study the fecal microbiota was sequenced in a depression study (26).
189 Forty-six patients with depression and 30 healthy controls were recruited. High-throughput
190 pyrosequencing showed that, according to the Shannon index, increased faecal bacterial
191 alpha-diversity was present in those currently depressed but not in a group who had
192 responded to treatment. This suggests that increased alpha diversity is a state rather than trait
193 marker for depression. Bacteroidetes, Proteobacteria, and Actinobacteria were increased,
194 whereas Firmicutes were significantly decreased. Despite the profound inter-individual
195 variability, levels of several predominant genera differed between the depressives and
196 controls. The depressives had increased levels of Enterobacteriaceae and Alistipes but
197 reduced levels of Faecalibacterium. The authors conclude that further studies are necessary to
198 elucidate the temporal and causal relationships between gut microbiota and depression and to
199 evaluate the suitability of the microbiome as a biomarker. In a study conducted at APC
200 Microbiome Ireland depressed patients had elevated cortisol output together with decreased
201 faecal microbial richness and surprisingly when rats were given a humanised microbiota from
202 depressed patients, as opposed to healthy controls, they developed a depressive phenotype
203 from both a behavioural and immune perspective(27).

204 **Depression co-morbidity**

205 Depression is frequently co-morbid with a variety of medical illnesses including
206 cardiovascular disease, metabolic syndrome and the gastrointestinal disorder irritable bowel
207 syndrome (IBS), which presents with abdominal pain or discomfort and an alteration of
208 bowel habit in the absence of gross pathology. In IBS an increase in pro-inflammatory
209 cytokines in the plasma has been reported(28) together with altered gut barrier function (29).
210 The latter is thought to lead to a ‘leaky gut’ and the passage of inflammatory molecules such
211 as lipopolysaccharide (LPS) from gram negative bacteria into the blood stream(30) with
212 subsequent activation of the immune system via toll-like receptors. The maternal separation
213 model of IBS supports the view of an altered gut microbiota in the condition together with a
214 pro-inflammatory phenotype.

215 It is possible that a poor quality diet may bring about the altered microbiota observed in
216 depression. Narrowing of dietary diversity with reduced intake of essential nutrients can
217 reduce availability of substrates for specific microbial growth and this could contribute to the
218 intestinal dysbiosis of depression.

219 **Diet and the microbiota**

220 Over recent decades, dietary patterns in Europe and elsewhere have undergone major
221 compositional changes, with increased intakes of red meat, high fat foods, and refined sugars.
222 This ‘Westernization’ of diets together with sedentary lifestyles results in modifications to the
223 gut microbiota, which may at least partially contribute to the increasing incidence of chronic
224 inflammatory disorders, such as cardiovascular disease, obesity, inflammatory bowel disorder
225 and depression (31). If we are to improve the nutritional value of food and positively impact
226 mental health, we need to more fully understand the biological interactions between the food
227 and microbiota. Many human studies have assessed dietary impact on the gut microbiota but
228 they are limited by the difficulties in controlling potential confounding variables especially

229 lifestyle behaviours. Studies are limited by the fact that the microbiota is sequenced from
230 faecal samples which provides no detail of the microbiota in various gut regions. With these
231 limitations in mind we have learned some useful lessons in relation to dietary patterns and
232 microbiota composition.

233 **Mediterranean diet and depression**

234 There is increasing evidence to support the view that poor quality diet is a risk factor for
235 major depression. Epidemiological studies have long demonstrated that those on a
236 Mediterranean diet suffer from less depression (32). Diets rich in fruit, vegetables, grains and
237 fish seem protective against depression while a diet of highly processed food and those with
238 a high sugar content predispose to depression(33). However, the data upon which these
239 conclusions are based are largely observational. There is a paucity of properly controlled
240 studies.

241 A recent study from Australia used a randomized controlled trial (RCT) design to investigate
242 the efficacy of a dietary program for the treatment of major depression(34). A structured
243 dietary support, focusing on improving diet quality using a modified Mediterranean diet was
244 compared to a social support control condition. Sixty-seven patients were recruited fulfilling
245 criteria for major depression and scoring 75 or less, out of a possible score of 104, on a
246 Dietary Screening Tool, a score which indicated a poor baseline diet. If patients were on
247 antidepressant medication or undergoing psychotherapy, they were required to be on the
248 same treatment for at least 2 weeks prior to study entry. The dietary intervention group
249 showed a significantly greater improvement in depression scores between baseline and
250 12 weeks than the social support control group. Overall, the results of this trial suggest that
251 improving diet may be a useful strategy for treating depression or at least as an adjunctive to
252 conventional therapies. Another study by Forsyth and colleagues reaches similar

253 conclusions(35). Furthermore, evidence is accumulating to support the view that the way in
254 which diet impacts health in general is mediated by the gut microbiota(36, 37).

255 If we assume that a Mediterranean diet is effective in the prevention and perhaps the
256 treatment of depression, what components of such a diet mediate these effects?

257 **Polyunsaturated fatty acid and mood**

258 The brain is a lipid-rich organ containing mostly complex polar phospholipids, sphingolipids,
259 gangliosides and cholesterol (38). These are involved in both the morphology and physiology
260 of neurones. The glycerophospholipids in the brain contain a high proportion of
261 polyunsaturated fatty acids (PUFA) derived from the essential fatty acids, linoleic acid and
262 alpha-linolenic acid. The main PUFAs in the brain are docosahexaenoic acid (DHA) derived
263 from the omega 3 fatty acid, alpha-linolenic acid, and arachidonic acid and docosatetraenoic
264 acid, both derived from the omega 6 fatty acid, linoleic acid(39).

265

266 Omega-3 fatty acid is derived from fish oil and there is considerable epidemiological
267 evidence to indicate that those with a diet rich in fish have a lower incidence of
268 cardiovascular disease than those with other diets(40). In recent times, the focus of attention
269 has been on the impact of omega-3 fatty acids on depression. Studies indicate that in
270 countries where there is a high consumption of fish there are lower rates of depression(41).
271 However, in many European countries in recent decades the intake of omega-3 PUFAs has
272 declined with a concomitant increase in omega-6 PUFA intake(42). Hibbeln was one of the
273 first to draw demonstrate the importance of omega-3 PUFAs in mental health: in a cross-
274 national study he found a significant negative correlation between worldwide fish
275 consumption and prevalence of depression (43). Subsequent studies have found altered
276 omega-6/omega-3 ratios in the plasma of depressed patients (44) and altered red blood cell

277 phospholipids (45). In post-mortem brain tissue lower DHA levels have been found in the
278 orbitofrontal cortex of in depressed patients.

279 Nemets and colleagues studied 22 depressed patients who failed to respond to antidepressant
280 therapy(46). The study had a parallel group, double-blind design in which EPA or placebo
281 was added to the on-going antidepressant. A significant effect of omega-3 compared with
282 placebo was found by week three of treatment. Peet et al examined the effects of EPA in 70
283 patients who had antidepressant resistant depression (47). Patients were randomised to
284 receive either placebo or EPA in doses of 1, 2 or 4 grams per day for 12 weeks. They
285 continued their antidepressant throughout. Forty-six of the 52 patients receiving the EPA and
286 14 of the 18 patients receiving placebo completed the 12 weeks study. The 1 gram per day
287 group showed a significantly better outcome than the placebo group. The authors conclude
288 that EPA 1 gram per day is an effective strategy for augmenting antidepressants in those who
289 are treatment resistant.

290 The results with DHA are inconclusive. Thirty-six subjects with major depression assigned to
291 receive DHA (2 g/d) for 6 weeks did not show differences in the score of the Montgomery-
292 Asberg Depression Rating Scale compared with the placebo-treated group (48). A number of
293 open label studies without appropriate controls report benefits. Given the lack of a placebo
294 control, these results need to be viewed with caution (49) .

295 A recent meta-analysis of fifteen trials (916 total participants) using omega-3 PUFAs as
296 either a mono or adjunctive therapy were analysed. Studies were selected based on
297 prospective, randomized, double-blinded, placebo-controlled study design, if depressive
298 episode was the primary complaint with or without comorbid medical conditions and, if
299 appropriate outcome measures were used to assess depressed mood (50). This meta-analysis
300 concluded that n-3 PUFA supplements with >60% of EPA (in a dose range of 200 to 2200

301 mg/d in excess of DHA) ameliorated the clinical condition. However, doses containing
302 primarily DHA or <60% EPA were not effective against primary depression.
303 It is known that EPA has a general immuno-suppressive effect with a capacity to suppress
304 inflammatory states. This may be relevant in the context of depression which is known to be
305 associated with an increase in the acute phase protein C-reactive protein (CRP) and pro-
306 inflammatory cytokines. A recent study demonstrated the capacity of polyunsaturated fatty
307 acids to impact the brain-gut axis by increasing levels of bifidobacteria (51). At this point it
308 seems reasonable to recommend fish in the diet of patients with depression but there is
309 insufficient data to recommend omega-3 PUFAs as either a mono or adjunctive therapy in the
310 disorder.

311 **Probiotics and depression**

312 Fermented foods have long been associated with a health benefit but only recently has that
313 benefit been extended to mental health. Numerous claims of therapeutic efficacy have been
314 made for probiotics but most claims are not substantiated by rigorous placebo controlled
315 studies. Psychobiotics are defined as bacteria which when ingested in adequate amounts have
316 a positive mental health benefit (52).

317 One therapeutic area where the benefits of probiotics have been established is in the common
318 gastrointestinal disorder IBS. Several placebo controlled studies indicate that a bifidobacteria
319 is highly effective in treating the condition(53). This is of relevance given the fact that up to
320 40% of patients with IBS have co-morbid depression and many bifidobacteria have anti-
321 inflammatory activity.

322 The principal rationale for the use of probiotics in treating major depression rests on their
323 potential for suppressing the pro-inflammatory component of depression. Can
324 probiotics/psychobiotics alter this aberrant immunology? It was shown that a bifidobacteria
325 in IBS switched the balance from a pro- to an anti-inflammatory cytokine response (54).

326 They found that in response to bifidobacteria treatment there was an increase in anti-
327 inflammatory IL-10 and a reduction in pro-inflammatory IL-12 activity. Similar findings
328 have been reported with *Lactobacillus acidophilus* (55).

329 There are several animal models of depression used for drug development. Using the
330 maternal separation model, *Bifidobacterium longum* 35624 was found to normalise behaviour
331 (17) and reduce corticosterone levels. This may indicate that the specific bifidobacteria strain
332 has an antidepressant action.

333 In a recent study, Benton and colleagues used a placebo controlled design to examine the
334 impact of probiotics on mood in healthy community based subjects. One-hundred and thirty-
335 two subjects with a mean age of 62 years were recruited(56). Over a three week period they
336 consumed either milk containing a probiotic or placebo daily. Mood was assessed at baseline
337 and after 10 and 20 days of treatment. Those who rated their mood as poorest at baseline
338 reported on average an improvement on probiotic by the end of the study. This improvement
339 was not noted on placebo. Whether these findings translate to a clinical sample remains to be
340 seen.

341 The effects of *Lactobacillus rhamnosus* HN001 given in pregnancy and postpartum on
342 symptoms of maternal depression and anxiety in the postpartum period was assessed (57).

343 Two hundred and twelve women were randomised to HN001 and 211 to placebo. Women
344 who received HN001 had significantly lower depression and anxiety scores in the postpartum
345 period. The results strongly support the view that the psychobiotic is protective against the
346 emergence of postpartum symptoms. This is the best human intervention study so far in the
347 literature.

348 Overall, it seems reasonable to conclude that psychobiotic studies in depressed patients are
349 urgently required.

350 **Prebiotics and depression**

351 Prebiotics are fibres metabolised by the microbiota and capable of increasing the levels of
352 good bacteria such as bifidobacteria. Prebiotics are found in vegetables such as celery,
353 Jerusalem artichoke, garlic etc. A number of small clinical controlled trials have assessed the
354 efficacy of certain prebiotics on psychological outcomes with promising results. Schmidt and
355 colleagues demonstrated that 3-week supplementation with a galactooligosaccharide (GOS)
356 prebiotic, which has been shown to stimulate bifidobacterial growth, in healthy volunteers
357 significantly reduced waking cortisol response, the stress hormone strongly linked to anxiety
358 and depression (58). Moreover, a B-GOS cohort demonstrated altered behavioural outcomes
359 through a decrease in attentional vigilance to negative versus positive information in a dot-
360 probe task compared to placebo. It is interesting to note, however, that fructooligosaccharide
361 (FOS) supplementation had no effect. These results suggest that shaping of microbiota
362 composition through prebiotic intake could influence behavioural outcomes. In humans,
363 prebiotic supplementation with trans-GOS not only enhanced bifidobacterial growth and
364 improved bloating symptoms, but in addition significantly reduced anxiety scores in IBS
365 sufferers (59).

366 **Polyphenols**

367 Polyphenols are undoubtedly the most numerous among the groups of phytochemicals
368 present in plants. They are broadly divided into flavonoids and non-flavonoids. Resveratrol
369 which is found in red wine has potent CNS actions. In an animal model of depression it has
370 been shown to reduce depressive type behaviours while attenuating the release of both
371 corticosterone and pro-inflammatory cytokines (60). It also exerts anti-oxidant activity acting
372 through sirtuins, is known to be metabolised by the microbiota and influences the
373 Firmicutes/Bacteroidetes ratio in the intestine (61). To date there are no published controlled
374 trials of resveratrol in depressed patients.

375 The polyphenol natural product curcumin possesses a variety of biological and
376 pharmacological properties. Curcumin was found to reduce salivary cortisol levels in
377 depressed patients relative to that seen in the placebo group(62). Recent data also indicates an
378 impact in increasing gut microbial diversity (63).

379 **MyNewGut Consortium recommendations**

380 The Mediterranean diet is associated with lower rates of depression, impacts optimally on the
381 gut microbiota and increasing evidence indicates that such a diet has antidepressant
382 effects(64). Patients with depression or vulnerability to depression should be encouraged to
383 enhance a plant-based diet with a high content of grains and fibres. High fibre diets are
384 associated with fewer symptoms of depression. When analyzed by the source of fiber, diets
385 higher in total fiber (more than 27 grams per day), and fiber from vegetables and
386 breads/cereals (mostly whole grain) were associated with a 42%, 46%, and 41% reduced
387 likelihood of having depressive symptoms, respectively(65). A decreased consumption of
388 red, meat especially of processed meat(66), a regular intake of fish(67) and fermented
389 foods(68) should be recommended. The intake of sodium and refined sugar should be
390 restricted. Vigorous aerobic exercise consistent with the age and physical health of the patient
391 should be encouraged(69).

392 393 **Author contributions**

394 TGD drafted the original manuscript. All authors contributed to discussion, editing and
395 approval of the final manuscript.

396 397 **Conflicts of interest**

398 APC Microbiome Ireland is funded by Science Foundation Ireland. T.G.D., C.S., J.F.C. and
399 Y.S. have conducted research funded by many pharmaceutical and food companies. T.G.D.,
400 C.S. J.F.C have received research funding from Mead Johnson, Cremo, Suntory Wellness,
401 Nutricia, 4D Pharma and DuPont.

402 403 **Acknowledgments**

404 The MyNewGut project is financially supported by a grant from the EU 7th Framework
405 Programme under Grant Agreement 613979. The EU is not liable for the content presented in
406 this publication.

407

- 409 1. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe.
410 *Eur J Neurol.* 2005;12 Suppl 1:1-27.
- 411 2. Ratheesh A, Davey C, Hetrick S, Alvarez-Jimenez M, Voutier C, Bechdorf A, et al. A systematic
412 review and meta-analysis of prospective transition from major depression to bipolar disorder. *Acta*
413 *Psychiatr Scand.* 2017;135(4):273-84.
- 414 3. Kendler KS. DSM disorders and their criteria: how should they inter-relate? *Psychol Med.*
415 2017;47(12):2054-60.
- 416 4. Sharma H, Santra S, Dutta A. Triple reuptake inhibitors as potential next-generation
417 antidepressants: a new hope? *Future Med Chem.* 2015;7(17):2385-406.
- 418 5. Korte SM, Prins J, Krajnc AM, Hendriksen H, Oosting RS, Westphal KG, et al. The many
419 different faces of major depression: it is time for personalized medicine. *Eur J Pharmacol.*
420 2015;753:88-104.
- 421 6. Leonard BE. Inflammation and depression: a causal or coincidental link to the
422 pathophysiology? *Acta Neuropsychiatr.* 2017:1-16.
- 423 7. Chopra K, Kumar B, Kuhad A. Pathobiological targets of depression. *Expert Opin Ther*
424 *Targets.* 2011;15(4):379-400.
- 425 8. Milaneschi Y, Bandinelli S, Penninx BW, Vogelzangs N, Corsi AM, Lauretani F, et al.
426 Depressive symptoms and inflammation increase in a prospective study of older adults: a protective
427 effect of a healthy (Mediterranean-style) diet. *Mol Psychiatry.* 2011;16(6):589-90.
- 428 9. Dinan TG, Cryan JF. Brain-Gut-Microbiota Axis and Mental Health. *Psychosom Med.*
429 2017;79(8):920-6.
- 430 10. Dinan TG, Cryan JF. Gut instincts: microbiota as a key regulator of brain development, ageing
431 and neurodegeneration. *J Physiol.* 2017;595(2):489-503.
- 432 11. Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, et al. Consumption of fermented milk
433 product with probiotic modulates brain activity. *Gastroenterology.* 2013;144(7):1394-401, 401 e1-4.
- 434 12. Allen AP, Hutch W, Borre YE, Kennedy PJ, Temko A, Boylan G, et al. *Bifidobacterium longum*
435 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in
436 healthy volunteers. *Transl Psychiatry.* 2016;6(11):e939.
- 437 13. Dinan TG, Cryan JF, Stanton C. Gut Microbes and Brain Development Have Black Box
438 Connectivity. *Biol Psychiatry.* 2018;83(2):97-9.
- 439 14. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-
440 enteric microbiota axis. *Nat Rev Gastroenterol Hepatol.* 2009;6(5):306-14.
- 441 15. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of
442 *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse
443 via the vagus nerve. *Proc Natl Acad Sci U S A.* 2011;108(38):16050-5.
- 444 16. Svensson E, Horvath-Puho E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, et al.
445 Vagotomy and subsequent risk of Parkinson's disease. *Ann Neurol.* 2015;78(4):522-9.
- 446 17. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic
447 *Bifidobacterium infantis* in the maternal separation model of depression. *Neuroscience.*
448 2010;170(4):1179-88.
- 449 18. Lyte M. Microbial endocrinology in the microbiome-gut-brain axis: how bacterial production
450 and utilization of neurochemicals influence behavior. *PLoS Pathog.* 2013;9(11):e1003726.
- 451 19. Lyte M. Microbial endocrinology and the microbiota-gut-brain axis. *Adv Exp Med Biol.*
452 2014;817:3-24.
- 453 20. Stilling RM, Dinan TG, Cryan JF. Microbial genes, brain & behaviour - epigenetic regulation of
454 the gut-brain axis. *Genes Brain Behav.* 2014;13(1):69-86.
- 455 21. El Aidy S, Dinan TG, Cryan JF. Immune modulation of the brain-gut-microbe axis. *Front*
456 *Microbiol.* 2014;5:146.

- 457 22. Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of cytokine-induced
458 depression. *Brain, behavior, and immunity*. 2002;16(5):575-80.
- 459 23. Lyte M, Varcoe JJ, Bailey MT. Anxiogenic effect of subclinical bacterial infection in mice in
460 the absence of overt immune activation. *Physiology & behavior*. 1998;65(1):63-8.
- 461 24. Bruch JD. Intestinal infection associated with future onset of an anxiety disorder: Results of a
462 nationally representative study. *Brain, behavior, and immunity*. 2016.
- 463 25. O'Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, et al. Early life
464 stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome
465 and psychiatric illnesses. *Biol Psychiatry*. 2009;65(3):263-7.
- 466 26. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered fecal microbiota composition in
467 patients with major depressive disorder. *Brain, behavior, and immunity*. 2015;48:186-94.
- 468 27. Kelly JR, Borre Y, C OB, Patterson E, El Aidy S, Deane J, et al. Transferring the blues:
469 Depression-associated gut microbiota induces neurobehavioural changes in the rat. *J Psychiatr Res*.
470 2016;82:109-18.
- 471 28. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, et al. Hypothalamic-
472 pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential
473 biomarker? *Gastroenterology*. 2006;130(2):304-11.
- 474 29. Bashashati M, Rezaei N, Shafieyoun A, McKernan DP, Chang L, Ohman L, et al. Cytokine
475 imbalance in irritable bowel syndrome: a systematic review and meta-analysis. *Neurogastroenterol*
476 *Motil*. 2014;26(7):1036-48.
- 477 30. Moloney RD, Desbonnet L, Clarke G, Dinan TG, Cryan JF. The microbiome: stress, health and
478 disease. *Mamm Genome*. 2014;25(1-2):49-74.
- 479 31. Galland L. Diet and inflammation. *Nutr Clin Pract*. 2010;25(6):634-40.
- 480 32. Sanchez-Villegas A, Henriquez P, Bes-Rastrollo M, Doreste J. Mediterranean diet and
481 depression. *Public Health Nutr*. 2006;9(8A):1104-9.
- 482 33. Akbaraly TN, Brunner EJ, Ferrie JE, Marmot MG, Kivimaki M, Singh-Manoux A. Dietary
483 pattern and depressive symptoms in middle age. *Br J Psychiatry*. 2009;195(5):408-13.
- 484 34. O'Neil A, Berk M, Itsiopoulos C, Castle D, Opie R, Pizzinga J, et al. A randomised, controlled
485 trial of a dietary intervention for adults with major depression (the "SMILES" trial): study protocol.
486 *BMC Psychiatry*. 2013;13:114.
- 487 35. Forsyth A, Deane FP, Williams P. A lifestyle intervention for primary care patients with
488 depression and anxiety: A randomised controlled trial. *Psychiatry Res*. 2015;230(2):537-44.
- 489 36. De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Stora A, Laghi L, et al. High-level adherence
490 to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. *Gut*.
491 2016;65(11):1812-21.
- 492 37. Haro C, Garcia-Carpintero S, Rangel-Zuniga OA, Alcalá-Díaz JF, Landa BB, Clemente JC, et al.
493 Consumption of Two Healthy Dietary Patterns Restored Microbiota Dysbiosis in Obese Patients with
494 Metabolic Dysfunction. *Mol Nutr Food Res*. 2017;61(12).
- 495 38. O'Brien JS, Sampson EL. Lipid composition of the normal human brain: gray matter, white
496 matter, and myelin. *J Lipid Res*. 1965;6(4):537-44.
- 497 39. Haug M. Essential fatty acids and the brain. *Can J Psychiatry*. 2003;48(3):195-203.
- 498 40. Sakai C, Ishida M, Ohba H, Yamashita H, Uchida H, Yoshizumi M, et al. Fish oil omega-3
499 polyunsaturated fatty acids attenuate oxidative stress-induced DNA damage in vascular endothelial
500 cells. *PLoS One*. 2017;12(11):e0187934.
- 501 41. Li F, Liu X, Zhang D. Fish consumption and risk of depression: a meta-analysis. *J Epidemiol*
502 *Community Health*. 2016;70(3):299-304.
- 503 42. Simopoulos AP. Essential fatty acids in health and chronic disease. *Am J Clin Nutr*. 1999;70(3
504 Suppl):560S-9S.
- 505 43. Hibbeln JR. Fish consumption and major depression. *Lancet*. 1998;351(9110):1213.

- 506 44. Dinan T, Siggins L, Scully P, O'Brien S, Ross P, Stanton C. Investigating the inflammatory
507 phenotype of major depression: focus on cytokines and polyunsaturated fatty acids. *J Psychiatr Res.*
508 2009;43(4):471-6.
- 509 45. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood
510 cell membranes of depressive patients. *Biol Psychiatry.* 1998;43(5):315-9.
- 511 46. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication
512 treatment for recurrent unipolar depressive disorder. *Am J Psychiatry.* 2002;159(3):477-9.
- 513 47. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in
514 patients with ongoing depression despite apparently adequate treatment with standard drugs. *Arch*
515 *Gen Psychiatry.* 2002;59(10):913-9.
- 516 48. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ. A double-blind, placebo-
517 controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major
518 depression. *Am J Psychiatry.* 2003;160(5):996-8.
- 519 49. Smith DJ, Sarris J, Dowling N, O'Connor M, Ng CH. Adjunctive low-dose docosahexaenoic acid
520 (DHA) for major depression: An open-label pilot trial. *Nutritional neuroscience.* 2017:1-5.
- 521 50. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic
522 acid (EPA) in clinical trials in depression. *The Journal of clinical psychiatry.* 2011;72(12):1577-84.
- 523 51. Costantini L, Molinari R, Farinon B, Merendino N. Impact of Omega-3 Fatty Acids on the Gut
524 Microbiota. *International journal of molecular sciences.* 2017;18(12).
- 525 52. Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. *Biol Psychiatry.*
526 2013;74(10):720-6.
- 527 53. Quigley EMM. The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and
528 Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). *Journal of clinical*
529 *medicine.* 2018;7(1).
- 530 54. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and
531 bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine
532 profiles. *Gastroenterology.* 2005;128(3):541-51.
- 533 55. Torii A, Torii S, Fujiwara S, Tanaka H, Inagaki N, Nagai H. Lactobacillus Acidophilus strain L-92
534 regulates the production of Th1 cytokine as well as Th2 cytokines. *Allergology international : official*
535 *journal of the Japanese Society of Allergology.* 2007;56(3):293-301.
- 536 56. Benton D, Williams C, Brown A. Impact of consuming a milk drink containing a probiotic on
537 mood and cognition. *European journal of clinical nutrition.* 2007;61(3):355-61.
- 538 57. Slykerman RF, Hood F, Wickens K, Thompson JMD, Barthow C, Murphy R, et al. Effect of
539 Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety:
540 A Randomised Double-blind Placebo-controlled Trial. *EBioMedicine.* 2017;24:159-65.
- 541 58. Schmidt K, Cowen PJ, Harmer CJ, Tzortzis G, Errington S, Burnet PW. Prebiotic intake reduces
542 the waking cortisol response and alters emotional bias in healthy volunteers. *Psychopharmacology*
543 *(Berl).* 2015;232(10):1793-801.
- 544 59. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-
545 galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.
546 *Aliment Pharmacol Ther.* 2009;29(5):508-18.
- 547 60. Yang XH, Song SQ, Xu Y. Resveratrol ameliorates chronic unpredictable mild stress-induced
548 depression-like behavior: involvement of the HPA axis, inflammatory markers, BDNF, and Wnt/beta-
549 catenin pathway in rats. *Neuropsychiatric disease and treatment.* 2017;13:2727-36.
- 550 61. Bird JK, Raederstorff D, Weber P, Steinert RE. Cardiovascular and Antiobesity Effects of
551 Resveratrol Mediated through the Gut Microbiota. *Advances in nutrition.* 2017;8(6):839-49.
- 552 62. Yu JJ, Pei LB, Zhang Y, Wen ZY, Yang JL. Chronic Supplementation of Curcumin Enhances the
553 Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-
554 Controlled Pilot Study. *Journal of clinical psychopharmacology.* 2015;35(4):406-10.
- 555 63. Zhang Z, Chen Y, Xiang L, Wang Z, Xiao GG, Hu J. Effect of Curcumin on the Diversity of Gut
556 Microbiota in Ovariectomized Rats. *Nutrients.* 2017;9(10).

- 557 64. Jacka FN, O'Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomised
558 controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). *BMC*
559 *Med.* 2017;15(1):23.
- 560 65. Gopinath B, Flood VM, Burlutsky G, Louie JC, Mitchell P. Association between carbohydrate
561 nutrition and prevalence of depressive symptoms in older adults. *Br J Nutr.* 2016;116(12):2109-14.
- 562 66. Oddy WH, Allen KL, Trapp GSA, Ambrosini GL, Black LJ, Huang RC, et al. Dietary patterns,
563 body mass index and inflammation: Pathways to depression and mental health problems in
564 adolescents. *Brain Behav Immun.* 2018;69:428-39.
- 565 67. Thesing CS, Bot M, Milaneschi Y, Giltay EJ, Penninx B. Omega-3 and omega-6 fatty acid levels
566 in depressive and anxiety disorders. *Psychoneuroendocrinology.* 2018;87:53-62.
- 567 68. Selhub EM, Logan AC, Bested AC. Fermented foods, microbiota, and mental health: ancient
568 practice meets nutritional psychiatry. *J Physiol Anthropol.* 2014;33:2.
- 569 69. Stubbs B, Vancampfort D, Firth J, Schuch FB, Hallgren M, Smith L, et al. Relationship between
570 sedentary behavior and depression: A mediation analysis of influential factors across the lifespan
571 among 42,469 people in low- and middle-income countries. *J Affect Disord.* 2018;229:231-8.

572

573

574

575

Figure Legends

576 Fig. 1 Shows how stress and poor diet combine to produce a gut dysbiosis and the symptoms
577 of depression

578

579 Fig. 2 Shows foods with high prebiotic content and capable of stimulating the growth of
580 'good' bacteria